Pharmaceutical company Indivior PLC (LON:INDV) reported on Monday the launch of the US Food and Drug Administration (FDA) approved PERSERIS (risperidone) first once-monthly for extended-release injectable suspension in the US for the treatment of schizophrenia in adults.
PERSERIS contains risperidone, a well-established medicine for schizophrenia, and uses an extended-release delivery system to form a subcutaneous (under the skin) depot that provides sustained levels of risperidone over one month, added the company.
The US FDA approval of PERSERIS was based on the company's Phase 3 study assessing the efficacy, safety and tolerability of the product in 354 patients aged 18 to 55 years with DSM-IV diagnosis of schizophrenia and an acute episode within eight weeks of screening for the study.
According to the company, PERSERIS efficacy was demonstrated by a statistically significant improvement in the primary clinical endpoint, Positive and Negative Syndrome Scale (PANSS) total score at Day 57. The systemic safety profile of PERSERIS was consistent with the known safety profile of oral risperidone.
In February 2019, the company is anticipating, and preparing for, a full promotional launch by the sales force for PERSERIS and contingent upon the US Court of Appeals upholding the preliminary injunction on generic buprenorphine and naloxone sublingual film against Dr. Reddy's Laboratories.
Additionally, PERSERIS will be distributed in a manner similar to all long-acting injectable antipsychotics and is available now for healthcare professionals to acquire through wholesalers, specialty distributors and pharmacies in an open network approach, concluded the company.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling